The global oncology clinical trials market size was valued at USD 18.55 billion in 2025 and is projected to grow from USD 20.11 billion in 2026 to USD 38.37 billion by 2034, registering a CAGR of 8.41% during the forecast period from 2026 to 2034. North America dominated the oncology clinical trials market with a market share of 47.92% in 2025.
The global market encompasses studies focused on evaluating innovative cancer therapeutics and treatment approaches across multiple cancer types, including breast, melanoma, colorectal, prostate, lung, and other malignancies. These trials span across different phases, such as Phase I, Phase II, Phase III, and Phase IV, each playing a critical role from initial safety assessment to post-marketing evaluation. Based on study design, oncology clinical trials are classified into interventional, observational, and expanded access studies, aimed at assessing new therapies, monitoring outcomes, and providing investigational treatments. The market ecosystem comprises pharmaceutical and biotechnology companies, clinical research organizations, academic institutes, and regulatory agencies that collectively drive clinical development, streamline patient recruitment, and support the advancement of targeted, immune oncology, and combination therapies to improve cancer treatment outcomes.
Download a Free Sample To learn more about this report,
Oncology research moved strongly toward cell and gene therapies (CGT), with CAR T and TCR platforms expanding beyond a few blood cancers into new tumor types. Regulatory bodies have continued to approve novel cell-based therapies, while numerous early-phase studies have been initiated globally. The FDA’s Oncology Center of Excellence (OCE) and CBER reported approvals of new cell-based products, many tied to precision diagnostics, while ClinicalTrials.gov showed a high number of ongoing CAR T/TCR studies across global sites.
This trend encouraged more phase 1/2 pipelines and fostered growth in multicentre trial networks. As more companies invested in CGT programs, the momentum enhanced the oncology clinical trials market, expanding innovation and increasing patient access to next-generation therapies.
The oncology landscape shifted from a niche use of radiopharmaceuticals to a broader pipeline across many cancers. Once limited to prostate and neuroendocrine tumors, radioligand therapies (RLTs) are now tested in earlier treatment lines, in combinations, and in new indications. Novartis AG reported in its annual report that the global expansion of Pluvicto and its acquisition of Mariana Oncology resulted in a strong commitment to radioligand innovation.
This momentum led more sponsors to design dose-finding and multicenter studies, which widened trial scope and patient groups. As more pharma companies invested in radiopharmaceutical development, the trend boosted the growth of the global market, driving innovation and opening more treatment options.
A key driver in the oncology clinical trials market is the strong pipeline of oncology drugs developed by domestic manufacturers, which fuels continuous clinical research and innovation in cancer therapies.
Such a factor demonstrated a strong pipeline that supported market growth and expanded treatment options for patients.
Investments by pharmaceutical companies to expand oncology research and manufacturing facilities are propelling market growth, as detailed in the table below.
Such strategic investments, combined with the aforementioned growth factors, are driving the global market during the analysis timeframe.
A challenge in the oncology clinical trials market is the escalating cost and complexity associated with conducting these studies. For example, in February 2024, the National Cancer Institute (NCI) highlighted that cancer trials were expensive to launch and operate, with numerous tests, lab work, and other protocol requirements extending study timelines.
Such complexity led to patient, caregiver, and researcher fatigue, potentially delaying the delivery of effective cancer prevention and treatment approaches.
The U.S. FDA’s Diversity Action Plans created a major opportunity for sponsors to design more inclusive oncology trials. These plans required companies to set clear enrolment goals by race, ethnicity, sex, and age, and to explain how they would meet them. This shift broadened the eligible patient base and improved trial relevance across real world populations. The FDA issued draft guidance under FDORA, and by late 2024, several sponsors had already updated protocols and added new community sites to align with diversity expectations.
This policy changed expanded trial networks, reduced recruitment barriers, and improved data generalizability. It is creating opportunities in the oncology clinical trials market by encouraging wider participation and sponsor confidence.
The Phase I segment is dominated the market in 2025 with a revenue share of 35.26%, owing to the increasing focus on early stage drug development, the rising number of novel oncology compounds entering clinical evaluation, and the need to assess safety and dosage in humans.
The Phase III is estimated to register the fastest CAGR of 9.23% during the forecast period, owing to the fact that phase III trials are the costliest as they involve a large number of participants. These trials also include long term safety studies conducted for regulatory approval and post marketing commitments.
Request Customizationto receive a tailored report.
The prostate cancer segment is anticipated to grow at a CAGR of 9.12% during 2026-2034. This growth is attributed to the rising prevalence of prostate cancer among aging populations, increasing awareness and early detection programs, and the development of innovative targeted therapies.
The breast cancer segment dominated the market, with a revenue share of 17.23%, owing to strong focus on early detection and personalized therapies. Continuous advancements in hormone, targeted, and immunotherapies drive extensive research activity. Moreover, substantial funding and awareness initiatives further accelerate clinical development in this segment.
The interventional studies segment dominated the market in 2025, with a revenue share of 75.63%. Interventional studies remained the backbone of oncology trials as they directly tested experimental therapies in controlled settings. Their ability to generate strong evidence on safety and efficacy made them the preferred approach for sponsors and regulators, driving continuous growth and innovation in the oncology clinical trials market.
The observational studies are estimated to register the fastest CAGR during the forecast period, due to the growing emphasis on long-term patient outcome tracking, and post-marketing surveillance. These studies provide valuable insights into treatment effectiveness, safety, and patient quality of life beyond controlled trial settings.
Speak to an Analystto discuss market opportunities.
The North America region dominated the market with a revenue share of 47.92% in 2025. North America’s market grew strongly because of the integration of electronic health records, biobanks, and population genomics projects that streamlined trial recruitment and monitoring. In the U.S., programs like NIH’s All of Us, which returned genomic results to over 100,000 participants by 2024, expanded trial-ready databases and enhanced personalized trial designs. This integration reduced patient identification barriers, improved trial diversity, and helped sponsors run oncology trials with greater speed and precision.
The U.S. market is anticipated to witness significant market growth owing to the government’s Cancer Moonshot program, which aimed to speed up cancer research by improving access to clinical trials and funding new trial models. In 2024, the NCI expanded community-based trial networks, making oncology studies available in more local and underserved areas. This helped improve trial participation and gave sponsors the chance to test therapies in real-world, diverse patient settings.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific region is the fastest-growing region with a CAGR of 9.52% during the forecast timeframe, owing to strong government support for precision medicine programs and heavy investments in genomics infrastructure. Countries like China, Japan, and South Korea improved access and affordability of cancer testing and trial participation. These initiatives encouraged more oncology trials across the region.
The Chinese market is anticipated to witness significant market growth owing to the regulatory flexibility that allows the use of real-world evidence (RWE) to support drug approvals. In 2024, the NMPA approved several oncology drugs using RWE from pilot zones like Hainan Boao. This approach encouraged more sponsors to run oncology trials in China.
In Europe, the market is witnessing steady growth driven by continuous advancements in healthcare infrastructure and patient care standards. Ongoing updates in diagnostic and treatment protocols across European nations have fostered the adoption of innovative therapeutic approaches. Several cancer centers across the region upgraded their facilities, aligning with new standards of cancer care. These enhancements have accelerated demand for novel oncology drugs and advanced clinical research, thereby propelling the growth of the oncology clinical trials market in Europe.
In Spain, the oncology clinical trials market is expanding significantly, supported by the rising cancer burden across age groups. As shown in the graph, cancer risk increases markedly with age, reaching 47.8% among men and 32.7% among women aged 80–84. This escalating incidence underscores the urgent need for advanced therapeutic interventions and the continued development of innovative oncology treatments through clinical research.
The oncology clinical trials market in the Middle East and Africa is witnessing steady growth driven by rapid advancements in cancer care infrastructure and accessibility to oncology drugs. Countries such as Saudi Arabia, the UAE, and South Africa are investing heavily in specialized cancer centers to enhance cancer diagnosis, treatment, and research capabilities.
In South Africa, the oncology clinical trials market is gaining traction with growing initiatives to enhance childhood cancer care. The implementation of the Paediatric Oncology Facility Integrated Local Evolution (ProFILE) tool is enabling systematic evaluation and improvement of pediatric oncology services nationwide. As cancer care delivery becomes more structured, equitable, and accessible, the rising demand for innovative oncology drugs and therapies for childhood cancers is expected to significantly contribute to the growth of South Africa’s market.
Across Latin America, the market is experiencing strong growth driven by the widespread adoption of national cancer screening initiatives. Countries such as Brazil, Mexico, and Argentina are implementing large-scale programs targeting breast, cervical, and colorectal cancers to enhance early detection and improve treatment outcomes. Government-supported efforts, including Brazil’s Unified Health System (SUS), are expanding access to preventive healthcare and promoting timely interventions, thereby increasing the demand for advanced diagnostics, oncology drugs, and clinical research in the region.
Mexico is emerging as a key hub for oncology clinical trials, supported by major investments from local pharmaceutical companies. The announcement by four Mexican pharmaceutical companies, Kener, Genbio, Neolpharma, and Neolsym, to invest over USD 722 million presents a significant opportunity for the country’s oncology clinical trials market. Amid chronic shortages of essential cancer medications and limited access to innovative therapies, this investment supports the federal government’s Plan México initiative, which aims to boost domestic pharmaceutical production and research capacity. By strengthening local capabilities for drug development and clinical research, these investments accelerated trial initiation, improved patient enrollment, and enhanced the availability of innovative oncology therapies, fostering a more dynamic and resilient clinical trials ecosystem in the country.
The global market is highly fragmented with the presence of numerous multinational pharmaceutical companies, contract research organizations (CROs), and emerging biotech firms actively engaged in developing innovative therapies.
OncoNova Therapeutics, Inc., is an emerging player in the global market, focusing on novel small-molecule therapeutics targeting hematologic malignancies and solid tumors.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Claims Management Market Size, Share, Growth, Analysis, Report, 2034
Biopharmaceutical Contract Manufacturing Market Size, Share, 2034
Pharmaceutical Stability and Storage Services Market Size, 2034
Vaccine Contract Manufacturing Market Size, Share, Growth, 2034
Dental Laboratories Market Size, Share, Growth, Analysis, 2034
Drug Testing Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com